Adaptive Exon 20 Insertion Mutant EGFR Inhibitors for Niche Environments

Publication ID: 24-11857513_0009_PTD

Published: October 28, 2025

Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Exon 20 Insertion Mutant EGFR Inhibitors for Niche Environments,” Published Technical Disclosure No. 24-11857513_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857513_0009_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,513.

Summary of the Inventive Concept

A specialized variation of selective inhibitors of exon 20 insertion mutant EGFR, tailored for treating lung cancer patients in high-altitude regions, disaster-stricken areas, remote locations, high-security facilities, and areas with limited medical resources.

Background and Problem Solved

The original patent disclosed a method for treating malignant lung tumors with EGFR having a mutation of exon 20 insertion. However, the patent did not address the specific challenges of treating patients in niche environments, such as high-altitude regions, disaster-stricken areas, remote locations, high-security facilities, and areas with limited medical resources. The new inventive concept adapts the original patent's technology to overcome these challenges.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system, method, or portable kit for treating EGFR-mutated lung cancer in niche environments. The system includes a selective inhibitor of exon 20 insertion mutant EGFR, adapted for use in low-oxygen environments, high-security facilities, or remote locations. The method involves administering the inhibitor and providing emergency medical support infrastructure, telemedicine support, or manual guidance for administering the inhibitor in extreme weather conditions. The portable kit includes the inhibitor and a manual for administering the inhibitor in extreme weather conditions.

Novelty and Inventive Step

The new claims introduce novel and non-obvious variations of the original patent's technology, including adaptations for high-altitude regions, disaster-stricken areas, remote locations, high-security facilities, and areas with limited medical resources. These adaptations involve modifications to the delivery mechanism, emergency medical support infrastructure, telemedicine support, and manual guidance, which are not obvious from the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different selective inhibitors of exon 20 insertion mutant EGFR, modifying the delivery mechanism for use in other niche environments, or incorporating additional features for monitoring patient response or tracking inhibitor administration.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in regions with high-altitude areas, disaster-prone zones, or limited medical resources. The target market includes pharmaceutical companies, healthcare providers, and government agencies focused on disaster relief and public health.

CPC Classifications

Section	Class	Group
A	A61	A61K31/519
A	A61	A61P35/00

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical oncology, specifically targeted cancer therapeutics for lung cancer with EGFR mutations, requiring advanced knowledge of molecular biology, pharmacology, and targeted drug design

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with a PhD in molecular oncology or pharmaceutical sciences, experienced in designing targeted cancer therapies, familiar with EGFR mutation mechanisms and adaptive drug delivery strategies

Obviousness Rationale

A person having ordinary skill would recognize that the source patent's core technology of EGFR exon 20 insertion inhibitors can be readily adapted to specialized delivery contexts without requiring inventive complexity. The fundamental molecular mechanism remains unchanged, with the PTD merely extending the application domain through predictable engineering modifications. These variations represent standard problem-solving approaches in precision oncology, where drug delivery optimization is a routine design challenge.

Obvious Combinations & Variations

Source Patent Element

Selective inhibitor targeting specific EGFR exon 20 insertion mutations

PTD Variation

Adapting inhibitor for use in high-altitude or low-oxygen environments

Obviousness Reasoning

Modifying drug delivery for environmental conditions is a predictable engineering solution within pharmaceutical development, involving standard formulation techniques known to those skilled in the art

Source Patent Element

Method of detecting and treating lung tumors with EGFR mutations

PTD Variation

Adding emergency medical support infrastructure and telemedicine monitoring

Obviousness Reasoning

Extending medical treatment protocols with remote monitoring is a standard approach in modern precision medicine, representing an obvious enhancement to existing treatment methodologies

Source Patent Element

Specific EGFR mutation inhibition technique

PTD Variation

Creating portable kit with administration manual for disaster-stricken areas

Obviousness Reasoning

Developing portable medical kits with clear instructions is a routine solution for expanding medical access, utilizing known packaging and documentation strategies

Source Patent Element

Cancer treatment method targeting specific molecular mutations

PTD Variation

Implementing secure delivery mechanisms for high-security facilities

Obviousness Reasoning

Adapting medical delivery to specialized security environments represents a straightforward design modification using established pharmaceutical distribution protocols

35 U.S.C. § 103 Summary: Based on US Patent 11857513's disclosure of EGFR exon 20 insertion inhibitors, the present publication demonstrates that a person of ordinary skill in the art would find the described variations obvious through standard engineering adaptations. The technical modifications represent predictable extensions of the original molecular targeting approach, employing routine problem-solving strategies within precision oncology drug development.

Original Patent Information

Patent Number	US 11,857,513
Title	Selective inhibitor of exon 20 insertion mutant EGFR
Assignee(s)	TAIHO PHARMACEUTICAL CO., LTD.